DocGo Inc. Research and Development Expense
DocGo Inc. (DCGO) reported Research and Development Expense of $3.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-17
- DocGo Inc. research and development expense for the quarter ending 2026-06-30 was $3.45M, a 16.54% increase year-over-year.
- DocGo Inc. research and development expense for the quarter ending 2026-03-31 was $3.71M, a 1.80% increase year-over-year.
- DocGo Inc. research and development expense for the quarter ending 2025-12-31 was $3.77M, a 2.37% increase year-over-year.
- DocGo Inc. research and development expense for the quarter ending 2025-09-30 was $3.19M, a 1.51% increase year-over-year.
- DocGo Inc. research and development expense for fiscal 2025 was $13.56M, a 17.03% increase from fiscal 2024.
- DocGo Inc. research and development expense for fiscal 2024 was $11.59M, a 6.73% increase from fiscal 2023.
- DocGo Inc. research and development expense for fiscal 2023 was $10.86M, a 101.65% increase from fiscal 2022.
- DocGo Inc. research and development expense for fiscal 2022 was $5.38M, a 62.19% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.45M 10-Q · filed 2026-08-17 | $7.15M 10-Q · filed 2026-08-17 | $10.92M derived: sum of 3 quarters · filed 2026-08-17 | $14.12M derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $3.71M 10-Q · filed 2026-05-11 | $7.48M derived: sum of 2 quarters · filed 2026-05-11 | $10.67M derived: sum of 3 quarters · filed 2026-05-11 | $13.63M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.97M derived: sum of 2 quarters · filed 2026-03-16 | $9.92M derived: sum of 3 quarters · filed 2026-08-17 | $13.56M 10-K · filed 2026-03-16 |
| 2025-09-30 | $3.19M 10-Q · filed 2025-11-10 | $6.15M derived: sum of 2 quarters · filed 2026-08-17 | $9.79M 10-Q · filed 2025-11-10 | $13.48M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-06-30 | $2.96M 10-Q · filed 2026-08-17 | $6.60M 10-Q · filed 2026-08-17 | $10.28M derived: sum of 3 quarters · filed 2026-08-17 | $13.43M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | $3.64M 10-Q · filed 2026-05-11 | $7.33M derived: sum of 2 quarters · filed 2026-05-11 | $10.47M derived: sum of 3 quarters · filed 2026-05-11 | $12.84M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.83M derived: sum of 2 quarters · filed 2026-03-16 | $9.20M derived: sum of 3 quarters · filed 2026-03-16 | $11.59M 10-K · filed 2026-03-16 |
| 2024-09-30 | $3.15M 10-Q · filed 2025-11-10 | $5.51M derived: sum of 2 quarters · filed 2025-11-10 | $7.90M 10-Q · filed 2025-11-10 | $11.09M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | $2.37M 10-Q · filed 2025-08-07 | $4.76M 10-Q · filed 2025-08-07 | $7.94M derived: sum of 3 quarters · filed 2026-03-16 | $11.18M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | $2.39M 10-Q · filed 2025-05-08 | $5.57M derived: sum of 2 quarters · filed 2026-03-16 | $8.81M derived: sum of 3 quarters · filed 2026-03-16 | $11.38M derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.42M derived: sum of 2 quarters · filed 2026-03-16 | $9.00M derived: sum of 3 quarters · filed 2026-03-16 | $10.86M 10-K · filed 2026-03-16 |
| 2023-09-30 | $3.24M 10-Q · filed 2024-11-07 | $5.81M derived: sum of 2 quarters · filed 2024-11-07 | $7.67M 10-Q · filed 2024-11-07 | $9.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.57M 10-Q · filed 2024-08-07 | $4.44M 10-Q · filed 2024-08-07 | $6.16M derived: sum of 3 quarters · filed 2025-02-27 | $7.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.86M 10-Q · filed 2024-05-08 | $3.59M derived: sum of 2 quarters · filed 2025-02-27 | $4.96M derived: sum of 3 quarters · filed 2025-02-27 | $6.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.09M derived: sum of 2 quarters · filed 2025-02-27 | $4.24M derived: sum of 3 quarters · filed 2025-02-27 | $5.38M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.37M 10-Q · filed 2023-11-06 | $2.52M derived: sum of 2 quarters · filed 2023-11-06 | $3.66M 10-Q · filed 2023-11-06 | $5.00M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $1.15M 10-Q · filed 2023-08-08 | $2.29M 10-Q · filed 2023-08-08 | $3.63M derived: sum of 3 quarters · filed 2024-02-28 | $4.48M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.14M 10-Q · filed 2023-05-09 | $2.48M derived: sum of 2 quarters · filed 2024-02-28 | $3.34M derived: sum of 3 quarters · filed 2024-02-28 | $4.00M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.19M derived: sum of 2 quarters · filed 2024-02-28 | $2.86M derived: sum of 3 quarters · filed 2024-02-28 | $3.32M 10-K · filed 2024-02-28 |
| 2021-09-30 | $854.62K 10-Q · filed 2022-11-08 | $1.52M derived: sum of 2 quarters · filed 2022-11-08 | $1.98M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $664.88K 10-Q · filed 2022-08-09 | $1.13M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $569.35K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $1.19M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |